359 related articles for article (PubMed ID: 16098464)
1. A conditional feedback loop regulates Ras activity through EphA2.
Macrae M; Neve RM; Rodriguez-Viciana P; Haqq C; Yeh J; Chen C; Gray JW; McCormick F
Cancer Cell; 2005 Aug; 8(2):111-8. PubMed ID: 16098464
[TBL] [Abstract][Full Text] [Related]
2. Constitutive activation of the Raf-MAPK pathway causes negative feedback inhibition of Ras-PI3K-AKT and cellular arrest through the EphA2 receptor.
Menges CW; McCance DJ
Oncogene; 2008 May; 27(20):2934-40. PubMed ID: 18059341
[TBL] [Abstract][Full Text] [Related]
3. Cell adhesion and EGFR activation regulate EphA2 expression in cancer.
Larsen AB; Stockhausen MT; Poulsen HS
Cell Signal; 2010 Apr; 22(4):636-44. PubMed ID: 19948216
[TBL] [Abstract][Full Text] [Related]
4. EphA2 receptor tyrosine kinase regulates endothelial cell migration and vascular assembly through phosphoinositide 3-kinase-mediated Rac1 GTPase activation.
Brantley-Sieders DM; Caughron J; Hicks D; Pozzi A; Ruiz JC; Chen J
J Cell Sci; 2004 Apr; 117(Pt 10):2037-49. PubMed ID: 15054110
[TBL] [Abstract][Full Text] [Related]
5. Activation of the EGFR gene target EphA2 inhibits epidermal growth factor-induced cancer cell motility.
Larsen AB; Pedersen MW; Stockhausen MT; Grandal MV; van Deurs B; Poulsen HS
Mol Cancer Res; 2007 Mar; 5(3):283-93. PubMed ID: 17374733
[TBL] [Abstract][Full Text] [Related]
6. Expression of EphA2 and Ephrin A-1 in carcinoma of the urinary bladder.
Abraham S; Knapp DW; Cheng L; Snyder PW; Mittal SK; Bangari DS; Kinch M; Wu L; Dhariwal J; Mohammed SI
Clin Cancer Res; 2006 Jan; 12(2):353-60. PubMed ID: 16428472
[TBL] [Abstract][Full Text] [Related]
7. Disruption of EphA2 receptor tyrosine kinase leads to increased susceptibility to carcinogenesis in mouse skin.
Guo H; Miao H; Gerber L; Singh J; Denning MF; Gilliam AC; Wang B
Cancer Res; 2006 Jul; 66(14):7050-8. PubMed ID: 16849550
[TBL] [Abstract][Full Text] [Related]
8. Activation of mitogen-activated protein kinase in estrogen receptor alpha-positive breast cancer cells in vitro induces an in vivo molecular phenotype of estrogen receptor alpha-negative human breast tumors.
Creighton CJ; Hilger AM; Murthy S; Rae JM; Chinnaiyan AM; El-Ashry D
Cancer Res; 2006 Apr; 66(7):3903-11. PubMed ID: 16585219
[TBL] [Abstract][Full Text] [Related]
9. Ligand binding up-regulates EphA2 messenger RNA through the mitogen-activated protein/extracellular signal-regulated kinase pathway.
Pratt RL; Kinch MS
Mol Cancer Res; 2003 Dec; 1(14):1070-6. PubMed ID: 14707290
[TBL] [Abstract][Full Text] [Related]
10. EphA2 as a novel molecular marker and target in glioblastoma multiforme.
Wykosky J; Gibo DM; Stanton C; Debinski W
Mol Cancer Res; 2005 Oct; 3(10):541-51. PubMed ID: 16254188
[TBL] [Abstract][Full Text] [Related]
11. Upregulation of EphA2 during in vivo and in vitro renal ischemia-reperfusion injury: role of Src kinases.
Baldwin C; Chen ZW; Bedirian A; Yokota N; Nasr SH; Rabb H; Lemay S
Am J Physiol Renal Physiol; 2006 Nov; 291(5):F960-71. PubMed ID: 16735461
[TBL] [Abstract][Full Text] [Related]
12. Ephrin-A1 is a negative regulator in glioma through down-regulation of EphA2 and FAK.
Liu DP; Wang Y; Koeffler HP; Xie D
Int J Oncol; 2007 Apr; 30(4):865-71. PubMed ID: 17332925
[TBL] [Abstract][Full Text] [Related]
13. Decreased tumorigenic potential of EphA2-overexpressing breast cancer cells following treatment with adenoviral vectors that express EphrinA1.
Noblitt LW; Bangari DS; Shukla S; Knapp DW; Mohammed S; Kinch MS; Mittal SK
Cancer Gene Ther; 2004 Nov; 11(11):757-66. PubMed ID: 15359289
[TBL] [Abstract][Full Text] [Related]
14. Receptor EphA2 activation with ephrinA1 suppresses growth of malignant mesothelioma (MM).
Nasreen N; Mohammed KA; Lai Y; Antony VB
Cancer Lett; 2007 Dec; 258(2):215-22. PubMed ID: 17949899
[TBL] [Abstract][Full Text] [Related]
15. EPHA2/EFNA1 expression in human gastric cancer.
Nakamura R; Kataoka H; Sato N; Kanamori M; Ihara M; Igarashi H; Ravshanov S; Wang YJ; Li ZY; Shimamura T; Kobayashi T; Konno H; Shinmura K; Tanaka M; Sugimura H
Cancer Sci; 2005 Jan; 96(1):42-7. PubMed ID: 15649254
[TBL] [Abstract][Full Text] [Related]
16. Immunocompetent mouse model of breast cancer for preclinical testing of EphA2-targeted therapy.
Noblitt LW; Bangari DS; Shukla S; Mohammed S; Mittal SK
Cancer Gene Ther; 2005 Jan; 12(1):46-53. PubMed ID: 15486559
[TBL] [Abstract][Full Text] [Related]
17. A kinase-dependent role for EphA2 receptor in promoting tumor growth and metastasis.
Fang WB; Brantley-Sieders DM; Parker MA; Reith AD; Chen J
Oncogene; 2005 Nov; 24(53):7859-68. PubMed ID: 16103880
[TBL] [Abstract][Full Text] [Related]
18. Ligation of EphA2 by Ephrin A1-Fc inhibits pancreatic adenocarcinoma cellular invasiveness.
Duxbury MS; Ito H; Zinner MJ; Ashley SW; Whang EE
Biochem Biophys Res Commun; 2004 Aug; 320(4):1096-102. PubMed ID: 15249202
[TBL] [Abstract][Full Text] [Related]
19. Impaired tumor microenvironment in EphA2-deficient mice inhibits tumor angiogenesis and metastatic progression.
Brantley-Sieders DM; Fang WB; Hicks DJ; Zhuang G; Shyr Y; Chen J
FASEB J; 2005 Nov; 19(13):1884-6. PubMed ID: 16166198
[TBL] [Abstract][Full Text] [Related]
20. 1Alpha,25-dihydroxyvitamin D3-mediated stimulation of steroid sulphatase activity in myeloid leukaemic cell lines requires VDRnuc-mediated activation of the RAS/RAF/ERK-MAP kinase signalling pathway.
Hughes PJ; Brown G
J Cell Biochem; 2006 Jun; 98(3):590-617. PubMed ID: 16440327
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
